Your browser doesn't support javascript.
loading
Exploring the Epigenetic Regulated Modulation of Fibroblast Growth Factor 21 Involvement in High-Fat Diet Associated Parkinson's Disease in Rats.
Kakoty, Violina; Kc, Sarathlal; Yang, Chih-Hao; Dubey, Sunil Kumar; Taliyan, Rajeev.
Afiliación
  • Kakoty V; Pharmacology Division, Department of Pharmaceutical Science, Lovely Professional University, Phagwara, Punjab 144411, India.
  • Kc S; Neuropsychopharmacology Division, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Rajasthan 333031, India.
  • Yang CH; Department of Non-Communicable Disease, Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
  • Dubey SK; Neuropsychopharmacology Division, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Rajasthan 333031, India.
  • Taliyan R; Department of Pharmacology, Taipei Medical University, Taipei 110, Taiwan.
ACS Chem Neurosci ; 14(4): 725-740, 2023 02 15.
Article en En | MEDLINE | ID: mdl-36694924
Imbalance in brain glucose metabolism and epigenetic modulation during the disease course of insulin resistance (IR) associated with Parkinson's disease (PD) risk remains a prime concern. Fibroblast growth factor 21 (FGF21), the metabolic hormone, improves insulin sensitivity and elicits anti-diabetic properties. Chronic stress during brain IR may modulate the FGF21 expression and its dynamic release via epigenetic modifications. Metformin regulates and increases the expression of FGF21 which can be modulating in obesity, diabetes, and IR. Hence, this study was designed to investigate the FGF21 expression modulation via an epigenetic mechanism in PD and whether metformin (MF), an autophagy activator, and sodium butyrate (NaB), a pan histone deacetylase inhibitor, alone and in combination, exert any therapeutic benefit in PD pathology exacerbated by high-fat diet (HFD). Our results portray that the combination treatment with MF and NaB potentially attenuated the abnormal lipid profile and increased motor performance for the rats fed with HFD for 8 weeks followed by intrastriatal 6-hydroxy dopamine administration. The enzyme-linked immunosorbent assay (ELISA) estimations of C-reactive protein, tumor necrosis factor-α, interleukin-1 beta and 6, and FGF21 exhibited extensive downregulation after treatment with the combination. Lastly, mRNA, western blot, histological, and cresyl violet staining depicted that the combination treatment can restore degenerated neuronal density and increase the protein level compared to the disease group. The findings from the study effectively conclude that the epigenetic mechanism involved in FGF21 mediated functional abnormalities in IR-linked PD pathology. Hence, combined treatment with MF and NaB may prove to be a novel combination in ameliorating IR-associated PD in rats, probably via the upregulation of FGF21 expression.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Resistencia a la Insulina / Metformina Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: ACS Chem Neurosci Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Resistencia a la Insulina / Metformina Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: ACS Chem Neurosci Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos